This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tanaka, H. Articles by Ito, E. Search for Related Content PubMed PubMed Citation Articles by Tanaka, H. Articles by Ito, E. Social Bookmarking                         What's this?

Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study

Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan, hirotana{at}cc.hirosaki-u.ac.jp

E. Oki

Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan

K. Tsugawa

Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan

K. Nonaka

Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan

K. Suzuki

Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan

E. Ito

Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan

The objective of the current work is to report the preliminary experience with tacrolimus (TL) administered as a single-dose daily for maintenance therapy of young patients with pediatric-onset, long-standing systemic lupus erythematosus (SLE). Six consecutive patients with long-standing SLE were recruited for a 6-month open-label trial of single-dose-daily administration of tacrolimus (3 mg/day) without dose up of concomitantly administered prednisolone (PDN). TL treatment was started at the time of the most recent flares. Data on the clinical and serologic lupus activity were collected prospectively. The baseline characteristics of the patients were: mean age, 20 years; urinary protein/creatinine ratio, 1.22 ± 1.94; serum C3 level, 70.8 ± 21.2 (normal, 79—152 mg/dL); serum complement hemolytic activity (CH50), 22.2 ± 10.3 (normal, 23—46 U/mL); serum anti-dsDNA antibody titer, 60.4 ± 71.7 IU/mL (normal, < 12.0 IU/mL); serum creatinine, 0.55 ± 0.11 mg/dL; European Consensus Lupus Activity Measurement (ECLAM) index, 5.2 ± 2.6. Despite the gradual tapering of the PDN dose, marked improvement as compared with the baseline values was observed in the ECLAM index examined at one and three months and serological parameters examined at three months after the start of treatment. After a 6-months' therapy, complete response was achieved in all of the patients (serum CH50 value, 27.7 ± 8.3 U/mL; serum anti-dsDNA antibody titer, 28.4 ± 27.9 U/mL and the ECLAM index, 1.2 ± 1.2 (P < 0.05), respectively), except in one patient who showed WHO class V lupus nephritis. No serious adverse effects were observed. These data suggest that TL, even when administered as a single-daily dose, is effective and safe for selected young patients with pediatric-onset, long-standing SLE. However, further studies on a larger number of patients are needed to confirm these results. Lupus (2007) 16, 896—900.

Key Words: adolescents • maintenance therapy • single-daily-dose administration • systemic lupus erythematosus • tacrolimus

Lupus, Vol. 16, No. 11, 896-900 (2007)
DOI: 10.1177/0961203307081914


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?